FindTrial
Sign In

A study to find out the effect of better planning in Radiotherapy on the outcome of throat Cancer in developing countries.

A Situation Analysis of National Radiotherapy Resources and Patterns of Care for Patients with Nasopharyngeal Carcinoma in Low-Middle Income Countries: Can Enhancing the Quality of Radiotherapy Planning Improve Outcomes - NPC Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/02/007893
Enrollment
300
Registered
2017-02-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patient of Nasopharyngeal Carcinoma

Interventions

None listed

Sponsors

International Atomic Energy Agency
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Informed consent in accordance with local regulations. 2. Age 18 years and above. 3. Histologically confirmed NPC, any WHO subtype UICC 7th Edition Stage III-IVB (i.e. any T3-4 or N2-3, and M0). 4. Primary RT planned with radical intent.

Exclusion criteria

Exclusion criteria: 1. Second primary malignant disease within the past 5 years, other than non melanomatous skin cancer or in situ carcinoma of cervix. 2. Pregnancy. 3. No previous radiotherapy to the head and neck region.

Design outcomes

Primary

MeasureTime frame
(I)A national survey on demographic data and RT facilities in participating countries (CRF-I). (II)A cross-sectional study on patient characteristics and patterns of care in participating centres (CRF-II). (III)A comparative study of RT planning and clinical outcomes before (Group A) and after (Group B) an educational intervention and encouragement of local peer review. (CRF-IIIA, B, C, D, E). Timepoint: Progression-Free Survival—

Secondary

MeasureTime frame
locoregional failure-free survival (LR-FFS; time to persistence/relapse at primary site and/or regional lymph nodes, censored by death) Distant failure-free survival (D-FFS: time to metastasis at distant sites, censored by death) Timepoint: Clinical outcome at a minimum of 2 years follow up after treatment site and/or regional lymph nodes, censored by death)—

Countries

Algeria, Australia, Austria, Canada, Egypt, France, Hong Kong, India, Indonesia, Pakistan, Philippines, Thailand, Tunisia, United Republic of Tanzania, United States of America, Viet Nam

Contacts

Public ContactDr Sarbani Ghosh Laskar

Tata Memorial Hospital

sarbanilaskar@gmail.com022-24177162

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026